ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Contract research giant WuXi files for Hong Kong offering

by Jean-François Tremblay
September 21, 2018 | APPEARED IN VOLUME 96, ISSUE 38

 

The contract research giant WuXi AppTec has filed for an initial public offering on Hong Kong’s stock exchange. WuXi delisted from the New York Stock Exchange in 2015, then relisted in Shanghai earlier this year, raising about $350 million. WuXi raised $500 million in Hong Kong last year when it listed WuXi Biologics, its biologics contract manufacturing unit. This time, WuXi AppTec plans to offer 10–15% of its stock to Hong Kong investors. Based on the value of WuXi’s stock in Shanghai, the new listing could raise $2 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment